An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma

A Linton1, Y Y Cheng1, K Griggs2

  • 1Asbestos Diseases Research Institute (ADRI), University of Sydney, Concord, NSW 2139, Australia.

British Journal of Cancer
|February 14, 2018
PubMed

Insights

This article corrects a previously published DOI. The correct Digital Object Identifier (DOI) is now updated for accurate citation and retrieval of the scientific content.

Area of Science:

  • Bibliometrics
  • Scientific Publishing

Background:

  • Accurate citation is crucial for scientific integrity.
  • Digital Object Identifiers (DOIs) ensure reliable access to research articles.

Purpose of the Study:

  • To correct an erroneous DOI associated with a published article.
  • To ensure proper attribution and discoverability of the research.

Main Methods:

  • Identification of the incorrect DOI.
  • Verification of the correct DOI through publisher records.
  • Correction of the DOI in the article's metadata and publication record.

Main Results:

  • The incorrect DOI (10.1038/bjc.2017.85) has been identified.
  • The correct DOI has been verified and updated.
  • The article is now accurately referenced.

Conclusions:

  • The correction ensures the article is correctly cited.
  • This update facilitates seamless access to the research for the scientific community.

Related Concept Videos

Pleural Effusion I: Introduction01:25

Pleural Effusion I: Introduction

Pleural effusion is an abnormal fluid accumulation in the pleural cavity, a narrow space between the lungs and the chest wall. It is not a disease per se but rather a symptom or indication of an underlying disease. In normal circumstances, this space contains a small amount of fluid (5 to 15 mL), a lubricant facilitating the non-frictional movement of the pleural surfaces.
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's...
4.5K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.8K
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.3K
Pleural Disorders: Types and Brief Description01:30

Pleural Disorders: Types and Brief Description

The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
723
Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
825
Therapeutic Index01:13

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
7.0K